Методы оценки когнитивного функционирования при аддиктивных заболеваниях и ВИЧ-инфекции

Проведен систематический анализ методов оценки когнитивного функционирования у русскоязычных пациентов с аддиктивными расстройствами и  ВИЧ-инфекцией. Для поиска статей использовалась база данных ELIBRARY, PubMed, Embase и  PsycInfo в  апреле 2020 г. Включены статьи, опубликованные за  последние 20 лет (2000–2020 гг.). Методология поиска основана на международных рекомендациях PRISMA. Выявлено, что большинство статей включает кросс-секционные исследования. В наркологических исследованиях редко учитывается влияние ВИЧ-инфекции на когнитивные нарушения. Применяются качественные и/или количественные методы, а  также инструменты скрининга. Наиболее часто используются следующие методики: заучивание 10 слов по А.Р.Лурия, таблицы Шульте, тест интеллекта Векслера и краткая шкала оценки психического статуса (MMSE). Показана необходимость разработки стандартизированного инструмента для изучения нейрокогнитивных особенностей пациентов с аддиктивными расстройствами с сопутствующей ВИЧ-инфекцией в России. 

1. Bates M.E., Bowden S.C., Barry D. Neurocognitive impairment associated with alcohol use disorders: Implications for treatment // Experimental and Clinical Psychopharmacology. 2002. Vol. 10, No. 3. Р. 193–212. https://doi.org/10.1037/1064-1297.10.3.193.

2. Bruijnen C.J.W.H., Dijkstra B.A.G., Walvoort S.J.W., Markus W., Van Der Nagel J.E.L., Kessels R.P.C., de Jong C.A.J. Prevalence of cognitive impairment in patients with substance use disorder // Drug and Alcohol Review. 2019. Vol. 38, No. 4. Р. 435–442. https://doi.org/10.1111/dar.12922.

3. Copersino M.L., Schretlen D.J., Fitzmaurice G.M., Lukas S.E., Faberman J., Sokoloff J., Weiss R.D. Effects of cognitive impairment on substance abuse treatment attendance: Predictive validation of a brief cognitive screening measure // American Journal of Drug and Alcohol Abuse. 2012. Vol. 38, No. 3. Р. 246–250. https://doi.org/10.3109/00952990.2012.670866.

4. Noël X., Sferrazza R., Van Linden M Der., Paternot J., Verhas M., Hanak C., Pelc I., Verbanck P. Contribution of frontal cerebral blood flow measured by 99mTc-bistate spect and executive function deficits to predicting treatment outcome in alcohol-dependent patients // Alcohol and Alcoholism. 2002. Vol. 37, No. 4. Р. 347–354. https://doi.org/10.1093/alcalc/37.4.347.

5. Bates M.E., Pawlak A.P., Tonigan J.S., Buckman J.F. Therapeutic mechanisms of change // Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2010. Vol. 20, No. 3. Р. 241–253. https://doi.org/10.1037/0893-164X.20.3.241.

6. Sømhovd M., Hagen E., Bergly T., Arnevik EA. The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment // Heliyon. 2019. Vol. 5, No. 3. Р. e01282. https://doi.org/10.1016/j.heliyon.2019.e01282.

7. Киржанова В.В., Григорова Н.И., Киржанов В.Н., Сидорюк О.В. Состояние и деятельность наркологической службы в Российской Федерации в 2017 году: Аналитический обзор. М.: ФГБУ «НМИЦ ПН им. В.П. Сербского» Минздрава России. 2019. 196 р. Ссылка активна на 09.12.2020. http://nncn.serbsky.ru/wp-content/uploads/2019/03/Анал_обзор_нарко_2017_фин-1-1.pdf

8. Heaton R.K., Clifford D.B., Franklin D.R., Woods S.P., Ake C., Vaida F., Ellis R.J., Letendre S.L., Marcotte T.D., Atkinson J.H., Rivera-Mindt M., Vigil O.R., Taylor M.J., Collier A.C., Marra C.M., Gelman B.B., McArthur J.C., Morgello S., Simpson D.M., McCutchan J.A., Abramson I., Gamst A., Fennema-Notestine C., Jernigan T.L., Wong J., Grant I. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter Study // Neurology. 2010. Vol. 75, No. 23. Р. 2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727.

9. Gisslén M., Price R.W., Nilsson S. The definition of HIV-associated neurocognitive disorders: Are we overestimating the real prevalence? // BMC Infectious Diseases. 2011. Vol. 11. Р. 2–5. https://doi.org/10.1186/1471-2334-11-356.

10. Nightingale S., Winston A. Measuring and managing cognitive impairment in HIV // AIDS. 2017. Vol. 31. S165–172. https://doi.org/10.1097/QAD.0000000000001402.

11. Alford K, Vera J.H. Cognitive Impairment in people living with HIV in the ART era: A Review // British Medical Bulletin. 2018. Vol. 127, No. 1. Р. 55–68. https://doi.org/10.1093/bmb/ldy019.

12. Kennedy C.A., Zerbo E. HIV-related neurocognitive disorders and drugs of abuse: mired in confound, surrounded by risk // Current Addiction Reports. 2014. Vol. 1, No. 3. Р. 229–236. https://doi.org/10.1007/s40429-014-0028-5.

13. Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research // Current drug abuse reviews. 2009. Vol. 2, No. 2. Р. 143–56. https://doi.org/10.1038/s41598-019-39414-9.

14. Winston A, Spudich S. Cognitive disorders in people living with HIV // The Lancet HIV. 2020. Vol. 7, No. 7. Р. e504–13. https://doi.org/10.1016/S2352-3018(20)30107-7.

15. To W.T., Vanheule S., Vanderplasschen W., Audenaert K., Vandevelde S. Screening for intellectual disability in persons with a substance abuse problem: Exploring the validity of the Hayes Ability Screening Index in a Dutch-speaking sample // Research in Developmental Disabilities. 2015. Vol. 36. Р. 498–504. https://doi.org/10.1016/j.ridd.2014.10.046.

16. Куков К., Радкова Д.М., Николова Д. Обзор методик нейропсихологического скрининга когнитивных функций и особенности их применения при исследовании больных с ВИЧ-инфекцией и синдромом приобретенного иммунодефицита // Вестник Южно-Уральского государственного университета. Серия: Психология. 2016. Т. 9, № 3. С. 16–23. https://doi.org/10.14529/psy160302.

17. Hagen E., Erga A.H., Hagen K.P., Nesvåg S.M., McKay J.R., Lundervold A.J., Walderhaug E. Assessment of executive function in patients with substance use disorder: A comparison of inventory- and performance-based assessment // Journal of Substance Abuse Treatment [Internet]. 2016. Vol. 66. Р. 1–8. https://doi.org/10.1016/j.jsat.2016.02.010.

18. Verdejo-Garcia A., Lorenzetti V., Manning V., Piercy H., Bruno R., Hester R., Pennington D., Tolomeo S., Arunogiri S., Bates M.E., BowdenJones H., Campanella S., Daughters S.B., Kouimtsidis C., Lubman D.I., Meyerhoff D.J., Ralph A., Rezapour T., Tavakoli H., Zare-Bidoky M., Zilverstand A., Steele D., Moeller S.J., Paulus M., Baldacchino A., Ekhtiari H. A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine // Frontiers in Psychiatry. 2019. Vol. 10. Р. 1–23. https://doi.org/10.3389/fpsyt.2019.00877.

19. Lookatch S.J., Elledge L.C., Anderson S., Shorey R.C., Stuart G.L., Moore T.M. Cognitive and psychological changes during 28-day residential substance use treatment // Addiction Research and Theory. 2017. Vol. 25, No. 4. Р. 334–341. https://doi.org/10.1080/16066359.2017.1281408.

20. Ramey T., Regier P.S. Cognitive impairment in substance use disorders // CNS Spectrums. 2019. Vol. 24, No. 1. Р. 102–113. https://doi.org/10.1017/S1092852918001426.

21. Kwako L.E., Momenan R., Litten R.Z., Koob G.F., Goldman D. Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders // Biological Psychiatry. 2016. Vol. 80, No. 3. Р. 179–189. https://doi.org/10.1016/j.biopsych.2015.10.024.

22. Antinori A., Arendt G., Becker JT., Brew BJ., Byrd DA., Cherner M., Clifford DB., Cinque P., Epstein LG., Gisslen M., Grant I., Heaton RK., Joseph J., Marra CM., Mcarthur JC., Nunn M., Price RW., Pulliam L., Robertson KR., Sacktor N., Valcour V., Wojna VE., Mount T., Medical S., Diego S., Hospital SR., Seattle W., Disorders N., Francisco S., Program N., Campus MS. Updated research nosology for HIV-associated neurocognitive disorders // Neurology. 2007. Vol. 69, No. 18. Р. 1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b.

23. Barry D., Petry N.M. Predictors of decision-making on the Iowa Gambling Task: Independent effects of lifetime history of substance use disorders and performance on the Trail Making Test // Brain and Cognition. 2008. Vol. 663. Р. 243–252. https://doi.org/10.1016/j.bandc.2007.09.001.

24. Dolan S.L., Bechara A., Nathan P.E. Executive dysfunction as a risk marker for substance abuse: the role of impulsive personality traits // Behavioral Sciences & the Law. 2008. Vol. 26. Р. 799–822. https://doi.org/10.1002/bsl.

25. Fernández-Serrano M.J., Pérez-García M., Schmidt Río-Valle J., Verdejo-García A. Neuropsychological consequences of alcohol and drug abuse on different components of executive functions // Journal of Psychopharmacology. 2010. Vol. 24, No. 9. Р. 1317–1332. https://doi.org/10.1177/0269881109349841.

26. Verdejo-García A., Bechara A., Recknor EC., Pérez-García M. Executive dysfunction in substance-dependent individuals during drug use and abstinence: An examination of the behavioral, cognitive and emotional correlates of addiction // Journal of the International Neuropsychological Society. 2006. Vol. 12, No. 3. Р. 405–415. https://doi.org/10.1017/S1355617706060486.

27. Goldstein R.Z., Leskovjan A.C., Hoff A.L., Hitzemann R., Bashan F., Khalsa S.S., Wang G.J., Fowler J.S., Volkow N.D. The severity of neuropsychological impairment in cocaine and alcohol addiction: Association with metabolism in the prefrontal cortex // Neuropsychology. 2004. Vol. 42, No. 11. Р. 1447–1458. https://doi.org/10.1016/j.neuropsychologia.2004.04.002

28. Hagen E., Erga A.H., Hagen K.P., Nesvåg S.M., McKay J.R., Lundervold A.J., Walderhaug E. Assessment of executive function in patients with substance use disorder: A comparison of inventory- and performance-based assessment // Journal of Substance Abuse Treatment [Internet]. 2016. Vol. 66. Р. 1–8. https://doi.org/10.1016/j.jsat.2016.02.010.

29. Verdejo-Garcia A., Lorenzetti V., Manning V., Piercy H., Bruno R., Hester R., Pennington D., Tolomeo S., Arunogiri S., Bates ME., BowdenJones H., Campanella S., Daughters S.B., Kouimtsidis C., Lubman DI., Meyerhoff DJ., Ralph A., Rezapour T., Tavakoli H., Zare-Bidoky M., Zilverstand A., Steele D., Moeller SJ., Paulus M., Baldacchino A., Ekhtiari H. A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine // Frontiers in Psychiatry. 2019. Vol. 10 (December). Р. 1–23. https://doi.org/10.3389/fpsyt.2019.00877.

30. Koob G.F., Le Moal M. Drug abuse: Hedonic homeostatic dysregulation // Science. 1997. Vol. 278, No. 5335. Р. 52–58. https://doi.org/10.1126/science.278.5335.52.

31. Moher D., Liberati A., Tetzlaff J., Altman DG., Altman D., Antes G., Atkins D., Barbour V., Barrowman N., Berlin JA., Clark J., Clarke M., Cook D., D’Amico R., Deeks JJ., Devereaux PJ., Dickersin K., Egger M., Ernst E., Gøtzsche PC., Grimshaw J., Guyatt G., Higgins J., Ioannidis J.P.A., Kleijnen J., Lang T., Magrini N., McNamee D., Moja L., Mulrow C., Napoli M., Oxman A., Pham B., Rennie D., Sampson M., Schulz KF., Shekelle PG., Tovey D., Tugwell P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement // PLoS Medicine. 2009. Vol. 6, No. 7. Р. e1000097. https://doi.org/10.1371/journal.pmed.1000097.

32. Березина А.А., Гвоздецкий А.Н., Климанова С.Г., Трусова А.В. Особенности принятия решений и эмоциональной регуляции у лиц с зависимостью от алкоголя // Вопросы наркологии. 2017. № 12. С. 133–144.

33. Полунина А.Г., Давыдов Д.М., Брюн Е.А. Нейропсихологические исследования когнитивных нарушений при алкоголизме и наркомании // Психологический журнал. 2004. Т. 25, № 5. С. 70–76.

34. Адрианова Е.Д., Дамулин И.В., Сиволап Ю.П. Когнитивные расстройства при алкоголизме // Наркология. 2013. Т. 12, № 6. С. 79–85.

35. Беляков Н.А., Медведев С.В., Трофимова Т.Н., Рассохин В.В., Дементьева Н.Е., Шеломов С.А. Механизмы поражения головного мозга при ВИЧ-инфекции // Вестник Российской академии медицинских наук. 2012. Т. 67, № 9. С. 4–12. https://doi.org/10.15690/vramn.v67i9.400.

36. Трофимова Т.Н., Катаева Г.В., Громова Е.А., Рассохин В.В., Боева Е.В., Симакина О.Е., Беляков Н.А. ВИЧ-ассоциированные нейрокогнитивные нарушения: диагностика, выявление причин и эффективность терапии // ВИЧ-инфекция и иммуносупрессии. 2018. Т. 10, № 4. С. 7–24. https://doi.org/10.22328/2077-9828-2018-10-4-7-24.

37. Folstein M.F., Folstein S.E., McHugh P.R. «Mini-mental state»: a practical method for grading the cognitive state of patients for the clinician // Journal of psychiatric research. 1975. Vol. 12, No. 3. Р. 189–198. https://doi.org/10.3744/snak.2003.40.2.021.

38. Mioshi E., Dawson K., Mitchell J., Arnold R., Hodges J.R. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening // International Journal of Geriatric Psychiatry. 2006. Vol. 21, No. 11. Р. 1078–1085. https://doi.org/https://doi.org/10.1002/gps.1610.

39. Ridley N., Batchelor J., Draper B., Demirkol A., Lintzeris N., Withall A. Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination. Addenbrooke’s Cognitive Examination–Revised., and Montreal Cognitive Assessment // Journal of Clinical and Experimental Neuropsychology. 2018. Vol. 40, No. 2. Р. 107–122. https://doi.org/10.1080/13803395.2017.1316970.

40. Wester A.J., Westhoff J., Kessels R.P.C., Egger J.I.M. The Montreal Cognitive Assessment (MoCA) is a measure of severity of amnesia in patients with alcohol-related cognitive impairments and Korsakov syndrome // Clinical Neuropsychiatry. 2013. Vol. 10, No. 3–4. Р. 134–141.

41. Sømhovd M., Hagen E., Bergly T., Arnevik E.A. The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment // Heliyon. 2019. Vol. 5, No. 3. Р. e01282. https://doi.org/10.1016/j.heliyon.2019.e01282.

42. Manning V., Gomez B., Guo S., Wong K.E., Assam P.N., Shih E., Chan-Yen. International Archives of Addiction Research and Medicine Screening for Cognitive Impairment in Asian Substance-Dependent Patients: MMSE versus MoCA // Int. Arch. Addict. Res. Med. 2016. Vol. 2, No. 2. Р. 1–5.

43. Ridley N., Batchelor J., Draper B., Demirkol A., Lintzeris N., Withall A. Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke’s Cognitive Examination–Revised, and Montreal Cognitive Assessment // Journal of Clinical and Experimental Neuropsychology. 2018. Vol. 40, No. 2. Р. 107–122. https://doi.org/10.1080/13803395.2017.1316970.

44. Toledo-Fernández A., Villalobos-Gallegos L., Marín-Navarrete R. Is the Mini-Mental State Examination (MMSE) useful for eligibility screening of research participants with substance use disorder? // Revista Internacional de Investigación en Adicciones. 2017. Vol. 2, No. 1. Р. 39–44. https://doi.org/10.28931/riiad.2016.1.06.

45. Copersino M.L., Fals-Stewart W, Fitzmaurice G, Schretlen DJ, Sokoloff J, Weiss RD. Rapid cognitive screening of patients with substance use disorders // Experimental and clinical psychopharmacology. 2009. Vol. 17, No. 5. Р. 337–344. https://doi.org/10.1038/jid.2014.371.

46. Alarcon R., Nalpas B., Pelletier S., Perney P. MoCA as a Screening Tool of Neuropsychological Deficits in alcohol-dependent Patients // Alcoholism: Clinical and Experimental Research. 2015. Vol. 39, No. 6. Р. 1042–1048. https://doi.org/10.1111/acer.12734.

47. Ewert V., Pelletier S., Alarcon R., Nalpas B., Donnadieu-Rigole H., Trouillet R., Perney P. Determination of MoCA Cutoff Score in Patients with Alcohol Use Disorders // Alcoholism: Clinical and Experimental Research. 2018 Vol. 42, No. 2. Р. 403–412. https://doi.org/10.1111/acer.13547.

48. Toledo-Fernández A, Marín-Navarrete R, Villalobos-Gallegos L, Salvador-Cruz J, Benjet C, Roncero C. Exploring the prevalence of substanceinduced neurocognitive disorder among polysubstance users, adding subjective and objective evidence of cognitive impairment // Psychiatry Research. 2020. Vol. 288, March. Р. 112944. https://doi.org/10.1016/j.psychres.2020.112944.

49. Fazeli P.L., Casaletto K.B., Paolillo E., Moore R.C., Moore D.J., the HNRP Group. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning // Journal of Clinical and Experimental Neuropsychology. 2017. Vol. 39, No. 9. Р. 842–853. https://doi.org/10.1080/13803395.2016.1273319.

50. Maillard A., Cabé N., Viader F., Pitel A.L. Neuropsychological deficits in alcohol use disorder: impact on treatment // Cognition and addiction [Academic Press]. 2020. Р. 103–128. https://doi.org/10.1016/B978-0-12-815298-0.00008-3.